Europe
Research involving participants of Britain’s oldest running birth cohort study has revealed that changes in blood pressure in those as young as 36 are linked to markers of poorer brain health in later life.
Alzheimer’s Research UK, the UK’s leading dementia research charity, is asking people to take part in a new survey that could help shape future treatments for dementia.
AstraZeneca announced that its Phase III DAPA-HF clinical trial of Farxiga (dapagliflozin) met its primary endpoint in decreasing cardiovascular death or the worsening of heart failure compared to placebo.
Sandra Horning, Roche’s chief medical officer and head of global product development, will retire from the company at the end of the year, leaving some big shoes to fill.
The U.S. FDA gave Nabriva Therapeutics a thumbs-up for both its oral and intravenous formulations of Xenleta (lefamulin) to treat community-acquired bacterial pneumonia in adults.
Innovation in drug delivery accelerating according to new Pharmapack Europe research
PharmaMar announced that the FDA agreed with PharmaMar’s proposal to file for accelerated approval its New Drug Application (NDA) for lurbinectedin monotherapy for the treatment of second-line SCLC.
A study conducted at the University of Eastern Finland demonstrated that a recently described T-cell subset, so-called peripheral T helper cells, may have a role in the development of type 1 diabetes.
The data-manipulation scandal with Novartis is widening, undermining investors’ trust in company chief executive officer Vas Narasimhan.
The $100 million tranche brings the company’s total fundraising efforts this over the past 18 months to $165 million.
PRESS RELEASES